Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2011

View Archived Issues

Tetraphase Pharmaceuticals describes multiple novel tetracyclines

GlycoVax discloses preclinical data on its proprietary glycoprotein vaccines

First-in-human data presented on risperidone-ISM formulation

Japanese team identifies new biomarker of pulmonary emphysema

Twelve-month data presented from IMPACT-DCM trial

MedImmune completes phase II tralokinumab trial

New chemokine CCR3 receptor antagonists patented by Axikin Pharmaceuticals

Pfizer synthesizes novel ghrelin receptor antagonists/inverse agonists

Janssen Pharmaceutica presents new DPP-I inhibitors

New JAK1 inhibitors claimed by Incyte

Pulmagen Therapeutics reports novel neutrophil elastase inhibitors

United Therapeutics subsidiary receives NIH grant to support glycobiology program

Inovio and VGX enter agreement to develop hepatitis vaccines

Dynavax reports immunogenicity data from phase III Heplisav trial

Cellceutix adds new indication to IND application for Kevetrin

Lilly seeks approval for new olanzapine formulation in Japan

Pharmasset expands ELECTRON trial

Targacept begins phase IIb trial of AZD-3480

Depomed launches once-daily Gralise

NanoCarrier and LFB Biotechnologies enter research collaboration

Insmed provides update on Arikace

Asahi Kasei Pharma to study transdermal patch formulation of Teribone using Zosano technology

Daval International reports phase II data on Aimspro

Takeda discontinues ramelteon development in Europe

Ligand Pharmaceuticals and Chiva Pharmaceuticals form global Fablyn agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Peptidream reveals milestone in Alnylam collaboration
BioWorld Science
Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery...